NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: ZZQ Peptides

Published 12 Nov 2026. 33-page investigative report on who is behind ZZQ Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 52 Finnrick lab tests, ZZQ Peptides' overall pass rate is 67% (35 pass / 16 fail). The record is uneven, not a uniform yes/no call: GHK-Cu and Retatrutide are the stronger lines, Tirzepatide is materially variable, and Tesamorelin is the clearest product-specific avoid. Stricter grading reinforces that split rather than rescuing the weaker products.

The public storefront creates a separate traceability problem. ZZQ claims manufacturer status, a lab and production line, HPLC/MS checks, and US overseas-warehouse access, but the reviewed pages disclose no legal seller, facility, quality lead, prices, batch/lot field, COA portal, or recall path. The catalog also mixes GLP-1/research items with Test E, Superdrol, and HGH, including a Superdrol page that pairs cycle language with a Test E vial image.

The contact layer is the sharper intelligence hook. ZZQ's current phone resolves on WhatsApp as Peptides~Quenna; indexed Quenna pages carried the same Shanghai address/number before the domain returned a parking page; and MingYu Peptide uses another mailbox on ZZQ's xtxinyao.cn email domain. That domain traces to a Haigui IT/web/email-services provider, while ZZQ's legal seller and UBO remain unresolved in the public sources reviewed.

No public affiliate-code network surfaced, which is a narrow positive. It leaves ZZQ thinly reviewed rather than affirmatively vetted, and it does not solve the core lot-linkage problem: a passing test is hard to map to the vial in hand when public labels and product pages do not expose coherent lot identifiers.

Inside the full report:

  • Per-product Finnrick analysis, methodology-divergence charts, and Appendix A lab table for all 5 tested products
  • Timeline of the old ZZQ number, current Quenna-branded WhatsApp account, and parked Quenna domain
  • Haigui provider-layer trail from WHOIS, DNS, Baidu Baike, BOSS Zhipin, and blocked registry checks
  • Network analysis of ZZQ, Quenna, MingYu, Sunnysky, EHZ, mailbox-domain, registrar, and template-platform leads
  • Catalog review covering the Superdrol/Test E mismatch, overseas-warehouse language, and missing batch/COA controls

Risk assessment

  • Corporate-identity and UBO opacity risk — high: No verified ZZQ legal seller, parent, manufacturer, executive, payment entity, or UBO is disclosed. The listed email domain is registered to an IT-services company; the manufacturer claims are not source-verifiable.
  • Contact-channel and sister-brand ambiguity risk — high: The current phone +852 4648 4383 is a WhatsApp Business account named Peptides~Quenna; search-index snippets recorded the same address/number on the Quenna storefront, which is now parked; MingYu uses another mailbox on xtxinyao.cn.
  • Brand-confusion and authenticity-verification risk — high: ZZQ provides no official-channel list, authorized-reseller list, signed COA portal, anti-counterfeit verification system, or working social links; copied-template peptide domains and sister-storefront signals increase buyer confusion.
  • Batch-traceability and recall-control risk — high: No batch/lot field or batch-tied COA appears on product pages. YouTube packaging visuals show product code, mg/vial, Mfg/Expiry and research-use text but no visible lot number, manufacturer, or facility code.
  • Controlled-product catalog and shipping-documentation risk — high: Catalog includes Test E 250, Clarus² Test E 300, Superdrol, and HGH alongside overseas-warehouse language, but no warehouse operator, importer, shipper, or fulfillment entity is disclosed.
  • Product-identification and direct-use content risk — high: The Superdrol page describes methasterone tablets but shows a vial labelled Test E 300, and includes dose/cycle/stacking language without public seller, batch, or COA controls.
  • Tesamorelin quality-reliability risk — high: Tesamorelin is ZZQ’s weakest tested line: 46.51%, 2 pass / 3 fail across 5 tests. A product-specific avoid signal.
  • Retatrutide identity and dose-reliability tail risk — high: Retatrutide’s aggregate 81.48% (15/18) is comparatively strong, but the retained field record includes a historical identity failure and severe fill-accuracy events. Require current batch-specific evidence.
  • Tirzepatide consistency risk — medium: Tirzepatide is materially weaker and more variable than GHK-Cu and Retatrutide: 64.44%, 11 pass / 8 fail across 19 tests. Require a current batch-specific independent result.
  • Cagrilintide quality-reliability risk — medium: Cagrilintide is early and small-sample at 56.27% (2 pass / 1 fail across 3 tests), and no public product page names it. Treat as unproven and fail-heavy.